Medical
Health
Therapy

BioTime

$1.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-3.42%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BioTime and other stocks, options, ETFs, and crypto commission-free!

About

BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Read More Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Employees
79
Headquarters
Alameda, California
Founded
1990
Market Cap
174.78M
Price-Earnings Ratio
2.56
Dividend Yield
0.00
Average Volume
660.21K
High Today
$1.17
Low Today
$1.12
Open Price
$1.14
Volume
143.60K
52 Week High
$2.81
52 Week Low
$0.66

Collections

Medical
Health
Therapy
Cancer Prevention
Research And Development
Technology

News

Yahoo FinanceMay 10

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Company’s retinal pigment epithelium transplant therapy currently in Phase I/IIa...

482
Seeking AlphaMay 10

BioTime, Inc. CEO Brian Culley on Q1 2019 Results - Earnings Call Transcript

BioTime, Inc. (NYSEMKT:BTX) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Ed Wirth - Chief Medical Officer Gary Hogge - Senior Vice President of Clinical & Medical Affairs, Conference Call Participants Kevin DeGeeter - Oppenheimer Jason McCarthy - Maxim Reni Benjamin - Raymond James Operator Welcome to the BioTime, Inc., First Quarter 2019 Ear...

156
Yahoo FinanceMay 9

BioTime Tops Q1 Earnings and Revenue Estimates

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

97

Earnings

-$0.58
-$0.21
$0.16
$0.53
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.06 per share
Actual
$0.30 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.